Загрузка...
Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?
More than 20 years ago, X-linked severe combined immunodeficiency (SCID-X1) appeared to be the best condition to test the feasibility of hematopoietic stem cell gene therapy. The seminal SCID-X1 clinical studies, based on first-generation gammaretroviral vectors, demonstrated good long-term immune r...
Сохранить в:
| Опубликовано в: : | Hum Gene Ther |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Mary Ann Liebert, Inc.
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4779287/ https://ncbi.nlm.nih.gov/pubmed/26790362 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/hum.2015.137 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|